The Future of Coagulation Diagnostics From Laboratory Testing to Better Patient Care

Laboratory coagulation testing plays a central role in the diagnosis and management of bleeding and thrombotic disorders.

From identifying coagulation factor deficiencies to assessing anticoagulant activity, accurate laboratory results are essential for guiding clinical decisions. However, routine tests do not always reflect the full complexity of hemostasis, and differences between laboratory methods can complicate diagnosis and patient management.

With advances in automation, specialized assays and artificial intelligence, coagulation diagnostics are entering a new era. Yet, ensuring reliable, standardized and clinically meaningful results remains a major challenge.

In a recent Hemostasis Today TV interview, hosted by Hermine Sayiyan, Hematology Resident, Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals, discussed the evolution of coagulation testing, the limitations of routine assays and the technologies shaping the future of laboratory diagnostics.

Beyond Routine Coagulation Tests

PT and aPTT remain essential investigations, but they cannot capture the full complexity of hemostasis. Patients with von Willebrand disease, platelet function disorders or factor XIII deficiency may have normal screening results.

Ifechidere emphasized the importance of interpreting laboratory findings alongside clinical presentation and bleeding history, with specialized investigations used when necessary.

Specialized Testing and Anticoagulant Interference

The increasing use of direct oral anticoagulants (DOACs) creates additional challenges because these medications can interfere with routine coagulation assays.

Drug-specific testing and specialized methodologies, including one-stage and chromogenic factor assays, can help clarify unexpected results and identify abnormalities that might otherwise be missed.

Standardization Remains a Major Challenge

Differences in reagents, analyzers, methodologies and laboratory protocols can lead to different results for the same patient sample across testing centers.

Ifechidere highlighted the importance of external quality assessment, harmonized procedures and laboratory training to improve consistency and reliability.

The ultimate goal is to ensure that patients receive comparable results regardless of where their samples are tested.

AI and Point-of-Care Testing: What Comes Next?

Artificial intelligence could help identify unusual laboratory patterns, integrate clinical information and support bleeding and thrombotic risk assessment.

Point-of-care technologies may also provide more comprehensive hemostatic information directly at the bedside, particularly in emergency and surgical settings.

Collaboration for Better Patient Care

Beyond technological advances, Ifeanyichukwu Ifechidere emphasized the importance of collaboration between biomedical scientists and clinicians. Effective communication improves test selection, result interpretation and clinical decision-making.

Her advice to early-career biomedical scientists was to build strong foundations in hemostasis, remain curious, pursue research, seek mentorship and recognize their contribution to patient care.

Ultimately, the future of coagulation diagnostics depends not only on technological innovation but also on accurate testing, laboratory standardization and collaboration. Behind every laboratory result is a patient whose diagnosis and treatment may depend on it.

Watch the Full Interview.

Stay tuned to Hemostasis Today TV for more expert insights in hemostasis.